Get the Stockscreener App
4.43
4.73%
-0.22
Neuronetics Inc stock is traded at $4.43, with a volume of 817.48K.
It is down -4.73% in the last 24 hours and up +8.58% over the past month.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
See More
Previous Close:
$4.65
Open:
$4.71
24h Volume:
817.48K
Relative Volume:
0.60
Market Cap:
$301.43M
Revenue:
$69.23M
Net Income/Loss:
$-33.10M
P/E Ratio:
-3.7542
EPS:
-1.18
Net Cash Flow:
$-39.26M
1W Performance:
-3.28%
1M Performance:
+8.58%
6M Performance:
+278.63%
1Y Performance:
+77.91%
1-Day Range:
$4.42
$4.75
1-Week Range:
$3.30
$4.815
52-Week Range:
$0.52
$5.92
Neuronetics Inc Stock (STIM) Company Profile
Name
Neuronetics Inc
Sector
Industry
Phone
877-600-7555
Address
3222 PHOENIXVILLE PIKE, MALVERN, PA
Compare STIM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STIM
Neuronetics Inc
|
4.43 | 301.43M | 69.23M | -33.10M | -39.26M | -1.18 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Neuronetics Inc Stock (STIM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-13-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-13-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jul-24-18 | Initiated | Canaccord Genuity | Buy |
View All
Neuronetics Inc Stock (STIM) Latest News
Neuronetics, Inc. (NASDAQ:STIM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$6.83 - Yahoo Finance
Neuronetics, Inc. (NASDAQ:STIM) Just Reported And Analysts Have Been Lifting Their Price Targets - simplywall.st
Neuronetics, Inc. (NASDAQ:STIM) Q1 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Neuronetics Q1 2025 misses EPS, stock drops 22% - Investing.com Nigeria
Neuronetics Inc (STIM) Q1 2025 Earnings Call Highlights: Revenue Surge Amidst Margin Challenges - Yahoo Finance
Neuronetics Inc (STIM) Q1 2025 Earnings Call Highlights: Revenue Surge Amidst Margin Challenges By GuruFocus - Investing.com Canada
Neuronetics Reports Strong Q1 2025 Growth - TipRanks
Neuronetics: Q1 Earnings Snapshot - CTPost
Neuronetics Q1 2025 Earnings Call Transcript - MarketBeat
Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of 2025 - marketscreener.com
Neuronetics Q1 2025 slides: Combined entity targets profitability by Q3 amid 84% revenue growth - Investing.com Canada
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Neuronetics (STIM) Surpasses Q1 Revenue Expectations with $32M | - GuruFocus
Neuronetics Reports First Quarter 2025 Financial and Operating R - GuruFocus
Neuronetics Inc (STIM) Q1 2025 Earnings: Revenue Surpasses Estimates at $32.0M, EPS Misses at $(0.21) - GuruFocus
Neuronetics reports inducement grant - Medical Buyer
Neuronetics Announces CFO Retirement Amidst Q1 Growth - TipRanks
Neuronetics, Inc. SEC 10-Q Report - TradingView
Neuronetics Reports First Quarter 2025 Financial and Operating Results - The Manila Times
Renaissance Technologies LLC Has $255,000 Position in Neuronetics, Inc. (NASDAQ:STIM) - Defense World
JPMorgan Chase & Co. Increases Stock Holdings in Neuronetics, Inc. (NASDAQ:STIM) - Defense World
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5 - GuruFocus
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Transcranial Magnetic Stimulator Market Generated - openPR.com
Neuronetics, Inc.'s (NASDAQ:STIM) 30% Jump Shows Its Popularity With Investors - simplywall.st
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category - IT Business Net
Geode Capital Management LLC Buys 8,466 Shares of Neuronetics, Inc. (NASDAQ:STIM) - Defense World
Taking the lead: Neuronetics Inc (STIM) - Sete News
Insider’s View: Deciphering Neuronetics Inc (STIM)’s Financial Health Through Ratios - DWinneX
Neuronetics Inc (STIM) stock on the rise: An overview - uspostnews.com
Why Neuronetics, Inc. (STIM) is Surging in 2025 - Insider Monkey
Transneural Therapeutics Appoints CNS Drug Development Expert, Mark A. Demitrack, MD, as Chief Research and Development Officer - The Malaysian Reserve
Neuronetics, Inc.'s (NASDAQ:STIM) market cap surged US$39m last week, individual investors who have a lot riding on the company were rewarded - simplywall.st
Neuronetics to Announce Q1 2025 Results and Host Live Conference Call on May 6 - MSN
Was there any good news for Neuronetics Inc (STIM) stock in the last session? - uspostnews.com
Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call | STIM Stock News - GuruFocus
Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call - The Manila Times
Medical Tech Leader Neuronetics Sets Q1 2025 Earnings Release: Key Details for Neurohealth Investors - Stock Titan
Neuronetics, Inc. (NASDAQ:STIM) Short Interest Update - Defense World
Neuronetics Reports 2024 Financial Results and Strategic Advances - MSN
Transcranial Magnetic Stimulator Market to Witness Remarkable - openPR.com
Neuronetics Announces Expanded Coverage for NeuroStar TMS to Treat Adolescent Depression - MSN
Even though Neuronetics (NASDAQ:STIM) has lost US$30m market cap in last 7 days, shareholders are still up 130% over 5 years - simplywall.st
Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression - The Manila Times
Major Insurance Breakthrough: NeuroStar's Teen Depression Treatment Now Covered for 15 Million Lives - Stock Titan
Neuronetics Revises Financial Results for Q4 and Full Year 2024 - MSN
Neuronetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Neuronetics: Explosive Growth Poised To Soar On FDA Breakthroughs (NASDAQ:STIM) - Seeking Alpha
Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results - The Manila Times
Neuronetics Some Non-Cash Revisions Made To Financial Statements Related To Co's Acquisition Of Greenbrook Tms & Shares Outstanding In Q4 - Marketscreener.com
Neuronetics Inc Stock (STIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):